Cerebellar degeneration

Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients

Retrieved on: 
Wednesday, November 15, 2023
Science, Other Science, Research, Public Relations, Investor Relations, General Health, Health, Communications, Clinical Trials, De Veenhuis, Movement disorder, DNA, CERP, Oculomotor apraxia, ChromaDex, Liver, Clinical trial, Cerebellar degeneration, Patient, Multimedia, Nicotinamide adenine dinucleotide, Immunodeficiency, Movement, DNA repair, Cerebellar ataxia, Cognition, Eye, University, Trial of the century, University of Oslo, Biomarker, NAD, Medical device, Ataxia–telangiectasia

The promising results demonstrate that long-term supplementation with Niagen NR effectively increased whole blood NAD+ levels up to fourfold, improved coordination, and enhanced eye movement while maintaining biomarkers of stable liver and kidney function in Ataxia Telangiectasia (AT) patients.

Key Points: 
  • The promising results demonstrate that long-term supplementation with Niagen NR effectively increased whole blood NAD+ levels up to fourfold, improved coordination, and enhanced eye movement while maintaining biomarkers of stable liver and kidney function in Ataxia Telangiectasia (AT) patients.
  • AT is a rare, inherited neurodegenerative disorder characterized by premature aging, cerebellar degeneration, immunodeficiency, and cancer predisposition.
  • View the full release here: https://www.businesswire.com/news/home/20231115900463/en/
    Newly published phase II clinical study demonstrates that supplementation with Niagen, patented nicotinamide riboside (NR), elevates NAD+ up to fourfold, improving motor coordination and eye movement in Ataxia Telangiectasia (AT) patients (Graphic: Business Wire)
    Building on a growing body of research, this is the second published study ( Veenhuis et al.
  • This growing body of research is promising as it demonstrates that NR supplementation may be a potential therapeutic strategy for AT patients.”

ChromaDex Shares Findings from First Clinical Study on Nicotinamide Riboside (NR) in Children, Highlighting Improvements for Prematurely Aging Patients with Ataxia-Telangiectasia (AT)

Retrieved on: 
Monday, October 18, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Risk, AT, Patient, Securities Exchange Act of 1934, Immunoglobulin G, Ageing, Antibody, Radboud University Medical Center, Doctor of Philosophy, Trial of the century, Neurodegeneration, Human, Serum, Securities Act of 1933, SEC, ChromaDex, Thought disorder, Regulatory affairs, NAD, Speech, Quality of life, Company, Cerebellar degeneration, Movement disorders, Annual report, Ataxia, Life expectancy, NASDAQ, Immunodeficiency, Disorder, Dysarthria, Research, Pharmaceutical industry, Vaccine

ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a first-of-its-kind clinical study published in the peer-reviewed journal, Movement Disorders , conducted by Michl A.A.P.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a first-of-its-kind clinical study published in the peer-reviewed journal, Movement Disorders , conducted by Michl A.A.P.
  • The study investigated ChromaDexs proprietary Niagen ingredient (patented nicotinamide riboside, or NR) in patients with ataxia-telangiectasia (AT), a rare, inherited neurodegenerative disorder characterized by premature aging, cerebellar degeneration, immunodeficiency, and cancer predisposition.
  • The study found that supplementation with NR improved ataxia scores and increased immunoglobulins, or antibodies, in the immune-compromised patients.
  • The results of this study are promising for those living with AT and are consistent with previous preclinical research.